Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
A combination of chemotherapy and endocrine therapy offers the promise of long-term recurrence-free survival for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer, despite having a biologically high risk of disease recurrence. Yesterday’s Late-Breaking…
Read More